In vitro dissolution profile comparison -: Statistics and analysis of the similarity factor, f2

被引:582
作者
Shah, VP
Tsong, Y
Sathe, P
Liu, JP
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Sci, Rockville, MD 20852 USA
[2] US FDA, CDER, Div Biometr 3, Off Epidemiol & Biometr, Rockville, MD 20857 USA
[3] Natl Cheng Kung Univ, Dept Stat, Tainan 70101, Taiwan
关键词
dissolution; similarity factor; estimation bias; bootstrap confidence interval;
D O I
10.1023/A:1011976615750
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To describe the properties of the similarity factor (f(2)) as a measure for assessing the similarity of two dissolution profiles. Discuss the statistical properties of the estimate based on sample means. Methods. The f(2) metrics and the decision rule is evaluated using examples of dissolution profiles. The confidence interval is calculated using bootstrapping method. The bias of the estimate using sample mean dissolution is evaluated. Results. 1. f(2) values were found to be sensitive to number of sample points, after the dissolution plateau has been reached. 2. The statistical evaluation of f(2) could be made using 90% confidence interval approach. 3. The statistical distribution of f(2) metrics could be simulated using 'Bootstrap' method. A relatively robust distribution could be obtained after more than 500 'Bootstraps'. 4. A statistical 'bias correction' was found to reduce the bias. Conclusions. The similarity factor f(2) is a simple measure for the comparison of two dissolution profiles. But the commonly used similarity factor estimate (f) over cap(2) is a biased and conservative estimate of f(2). The bootstrap approach is a useful tool to simulate the confidence interval.
引用
收藏
页码:889 / 896
页数:8
相关论文
共 16 条
[1]  
[Anonymous], 1997, FDA GUIDANCE IND EXT
[2]  
[Anonymous], 1997, THER INNOV REGUL SCI, DOI [DOI 10.1177/009286159703100426, 10.1177/009286159703100426]
[3]  
Chow S C, 1997, J Biopharm Stat, V7, P241, DOI 10.1080/10543409708835184
[4]  
EFRON B, 1993, INTO BOOTSTRAP
[5]  
Johnson R.A., 1982, APPL MULTIVARIATE ST
[6]  
Ju H.L., 1997, DRUG INFORM J DRUG I, V31, P1273, DOI [10.1177/ 009286159703100427, DOI 10.1177/009286159703100427]
[7]  
Moore J.W., 1996, PHARM TECHNOL, V20, P64, DOI DOI 10.1017/CCOL521633230.011
[8]  
Polli J. E., 1996, DRUG INF J, V30, P1113, DOI [10.1177/00928615960300 0428, DOI 10.1177/009286159603000428]
[9]   Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets [J].
Polli, JE ;
Rekhi, GS ;
Augsburger, LL ;
Shah, VP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (06) :690-700
[10]   In-vitro dissolution profile comparison: Statistics and analysis, model dependent approach [J].
Sathe, PM ;
Tsong, Y ;
Shah, VP .
PHARMACEUTICAL RESEARCH, 1996, 13 (12) :1799-1803